Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1952 1
1982 1
1985 1
1987 1
1988 1
1989 1
1990 3
1991 2
1992 1
1994 1
1995 2
1997 2
1999 1
2000 4
2001 2
2002 2
2004 1
2005 4
2006 1
2007 4
2008 3
2009 1
2010 3
2011 8
2012 14
2013 14
2014 21
2015 20
2016 19
2017 15
2018 17
2019 12
2020 19
2021 12
2022 15
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. Among authors: versari a. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: versari a. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation.
Casali M, Lauri C, Altini C, Bertagna F, Cassarino G, Cistaro A, Erba AP, Ferrari C, Mainolfi CG, Palucci A, Prandini N, Baldari S, Bartoli F, Bartolomei M, D'Antonio A, Dondi F, Gandolfo P, Giordano A, Laudicella R, Massollo M, Nieri A, Piccardo A, Vendramin L, Muratore F, Lavelli V, Albano D, Burroni L, Cuocolo A, Evangelista L, Lazzeri E, Quartuccio N, Rossi B, Rubini G, Sollini M, Versari A, Signore A. Casali M, et al. Among authors: versari a. Clin Transl Imaging. 2021;9(4):299-339. doi: 10.1007/s40336-021-00445-w. Epub 2021 Jul 10. Clin Transl Imaging. 2021. PMID: 34277510 Free PMC article. Review.
PRRT: identikit of the perfect patient.
Albertelli M, Dotto A, Di Dato C, Malandrino P, Modica R, Versari A, Colao A, Ferone D, Faggiano A; NIKE. Albertelli M, et al. Among authors: versari a. Rev Endocr Metab Disord. 2021 Sep;22(3):563-579. doi: 10.1007/s11154-020-09581-6. Rev Endocr Metab Disord. 2021. PMID: 32978685 Free PMC article. Review.
CT protocol optimisation in PET/CT: a systematic review.
Bertolini V, Palmieri A, Bassi MC, Bertolini M, Trojani V, Piccagli V, Fioroni F, Cavuto S, Guberti M, Versari A, Cola S. Bertolini V, et al. Among authors: versari a. EJNMMI Phys. 2020 Mar 16;7(1):17. doi: 10.1186/s40658-020-00287-x. EJNMMI Phys. 2020. PMID: 32180029 Free PMC article. Review.
Do we need FDG-PET/CT to assess atherosclerosis?
Pipitone N, Salvarani C, Versari A. Pipitone N, et al. Among authors: versari a. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):247-248. doi: 10.1007/s00259-016-3568-1. Eur J Nucl Med Mol Imaging. 2017. PMID: 27864590 Clinical Trial. No abstract available.
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Luminari S, et al. Among authors: versari a. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. J Clin Oncol. 2022. PMID: 34709880 Clinical Trial.
Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson's disease.
Gessani A, Cavallieri F, Fioravanti V, Campanini I, Merlo A, Di Rauso G, Damiano B, Scaltriti S, Bardi E, Corni MG, Antonelli F, Cavalleri F, Molinari MA, Contardi S, Menozzi E, Fraternali A, Versari A, Biagini G, Fraix V, Pinto S, Moro E, Budriesi C, Valzania F. Gessani A, et al. Among authors: versari a. Sci Rep. 2023 Jul 15;13(1):11462. doi: 10.1038/s41598-023-38555-2. Sci Rep. 2023. PMID: 37454168 Free PMC article.
Usefulness of PET in recognizing and managing vasculitides.
Pipitone NAM, Versari A, Salvarani C. Pipitone NAM, et al. Among authors: versari a. Curr Opin Rheumatol. 2018 Jan;30(1):24-29. doi: 10.1097/BOR.0000000000000459. Curr Opin Rheumatol. 2018. PMID: 29035930 Review.
Molecular Imaging of Inflammatory Arthritis and Related Disorders.
Jamar F, Versari A, Galli F, Lecouvet F, Signore A. Jamar F, et al. Among authors: versari a. Semin Nucl Med. 2018 May;48(3):277-290. doi: 10.1053/j.semnuclmed.2017.12.005. Epub 2018 Jan 10. Semin Nucl Med. 2018. PMID: 29626944 Review.
214 results